Table 2

Prediction of ADNI-mem, tau (flortaucipir) and Aβ (florbetapir) PET meta ROI SUVR tracer uptake for plasma p-Tau181 and plasma NfL baseline concentrations and rates of change over time (slope)

VariableEntire cohort (N=503)A−TN− (N=192)A+TN− (N=101)A+TN+ (N=121)A−TN+ (N=89)
ADNI-mem B (s.B)p valueB (s.B)P valueB (s.B)P valueB (s.B)P valueB (s.B)P value
Plasma p-tau181 log10 baseline−0.64 (-0.16)<0.001−0.13 (-0.05)0.30−0.28 (-0.07)0.29−1.59 (-0.26)<0.001−0.42 (-0.12)0.12
Plasma NfL log10 baseline−0.88 (-0.16)<0.001−0.38 (-0.09)0.08−0.22 (-0.04)0.56−0.88 (-0.14)0.07−1.23 (-0.26)<0.001
Plasma p-tau181 slope−2.49 (-0.02)0.38−3.47 (-0.05)0.23−5.39 (-0.05)0.400.82 (0.01)0.93−2.77 (-0.03)0.69
Plasma NfL slope−12.89 (-0.11)<0.001−10.61 (-0.12)0.01−8.16 (-0.08)0.24−19.30 (-0.17)0.020.94 (0.01)0.91
Tau PET Entire cohort (N=196) A−TN− (N=83) A+TN− (N=40) A+TN+ (N=41) A−TN+ (N=32)
Plasma p-tau181 log10 baseline0.68 (0.28)<0.0010.03 (0.05)0.680.15 (0.10)0.592.23 (0.35)0.030.24 (0.14)0.50
Plasma NfL log10 baseline0.66 (0.18)0.020.08 (0.08)0.55−0.09 (-0.04)0.821.22 (0.18)0.290.07 (0.03)0.89
Plasma p-tau181 slope2.92 (0.04)0.550.14 (0.01)0.9310.04 (0.21)0.177.69 (0.05)0.772.46 (0.04)0.82
Plasma NfL slope23.21 (0.27)<0.0010.83 (0.04)0.750.82 (0.25)0.1249.20 (0.32)0.04719.52 (0.31)0.097
Amyloid PET Entire cohort (N=103) A−TN− (n=51) A+TN− (n=19) A+TN+ (n=16) A−TN+ (N=17)
Plasma p-tau181 log10 baseline0.76 (0.26)0.01−0.04 (-0.03)0.860.77 (0.18)0.520.56 (0.21)0.450.07 (0.04)0.88
Plasma NfL log10 baseline1.08 (0.23)0.030.31 (0.14)0.810.53 (0.07)0.800.35 (0.10)0.700.10 (0.04)0.91
Plasma p-tau181 slope5.88 (0.07)0.500.01 (0.12)0.4457.49 (0.36)0.11−13.94 (-0.15)0.65−5.45 (-0.10)0.71
Plasma NfL slope14.92 (0.14)0.168.76 (0.17)1.1812.24 (0.09)0.6910.04 (-0.13)0.6219.69 (0.32)0.15
  • Analyses adjusted for age, sex and the time difference between baseline and ADNI-mem assessment/PET scan. Baseline cognition was included in the model when predicting ADNI-mem at follow-up.

  • Aβ, amyloid β; A+/−, Amyloid-β positive/negative; ADNI, Alzheimer’s Disease Neuroimaging Initiative; ATN, Aβ deposition, tau pathology and neurodegeneration; B, beta (slope); NfL, neurofilament light protein; p-tau181, plasma phosphorylated tau 181; s.B, standardised beta; TN+/−, Tau/Neurodegeneration positive/negative.